Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome
Posted inCardiology Internal Medicine news

Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome

A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with alirocumab effectively mitigates this risk while significantly reducing biomarker levels.
Procainamide Challenge for Brugada Syndrome: Establishing Diagnostic Safety and the Reassuring Prognosis of Induced Patterns
Posted inCardiology news

Procainamide Challenge for Brugada Syndrome: Establishing Diagnostic Safety and the Reassuring Prognosis of Induced Patterns

A large-scale registry study confirms that procainamide infusion is exceptionally safe for Brugada syndrome diagnosis, with high sensitivity and specificity. Crucially, asymptomatic patients with a procainamide-induced type 1 pattern demonstrate a very low risk of future arrhythmic events, potentially guiding more conservative management strategies.
Long COVID-19 in Pregnancy: Elevated Risk Amidst Mild Omicron Infection in a Boosted Vaccinated Cohort During COVID-19 Endemicity
Posted inClinical Updates Infectious Diseases news OB/GYN & Women's Health

Long COVID-19 in Pregnancy: Elevated Risk Amidst Mild Omicron Infection in a Boosted Vaccinated Cohort During COVID-19 Endemicity

Pregnant women show increased risk of long COVID-19 post-SARS-CoV-2 infection during Omicron predominance despite mild disease, yet incidence remains modest in a highly vaccinated cohort, highlighting vaccination’s protective role amidst emerging endemicity.
Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
Posted inCardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.
Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM
Posted inCardiology news

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offering a simple yet powerful tool for clinical cardiopulmonary exercise testing.
A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Posted inCardiology news

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic peptides, provides a robust staging system across multiple assay platforms.
Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution
Posted inDermatology news

Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution

This Phase 2b randomized clinical trial demonstrates that vixarelimab, a monoclonal antibody targeting OSMRβ, significantly reduces pruritus and promotes skin lesion clearance in patients with moderate-to-severe prurigo nodularis, offering a potent, dose-dependent therapeutic option with a favorable safety profile.